Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Blood Test Evaluated for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 11 Jun 2014
Tumor-derived aberrant DNA can be detectable in blood and blood tests have the potential to improve screening for colorectal cancer.

A new blood test for bowel cancer based on two genes that are frequently hyper-methylated in colorectal adenoma and cancer (CRC) tissues, has been assessed for accuracy.

Scientists at Flinders University (Adelaide, SA, Australia) working with their Dutch colleagues enrolled 2,187 volunteers with a mean age of 62 years, 52% of which were male. More...
The patients were scheduled for colonoscopy for any reason, or for resection of colonic neoplasia, and were included if they provided sufficient plasma. The test was run successfully on 2,139 plasma specimens including 30 sample pairs taken pre- and post-surgical removal of neoplastic lesions.

Circulating cell-free DNA was extracted from plasma samples and bisulphite converted. Levels of recovered DNA and methylated Branched Chain Amino-Acid Transaminase 1, Cytosolic (BCAT1) and IKAROS Family Zinc Finger 1 (IKZF1) DNA were simultaneously determined using multiplexed quantitative polymerase chain reactions (qPCR) (Clinical Genomics; Sydney, NSW, Australia). A plasma sample was defined as positive if amplified target sequence signal above background fluorescence was present in any of three replicates in the BCAT1 or IKZF1 qPCR assay. Sensitivity and specificity for neoplasia were estimated as the primary outcome measures.

The two-gene blood test, BCAT1 and/or IKZF1 positive, successfully identified 85/130 (65.4%) of CRC cases. The successful detection rate increased to 73% for cancers that are Stage II or higher. The 12 BCAT1/IKZF1 methylation-positive CRC subjects with paired pre- and post-surgery plasma showed reduction in methylation signal after surgery, with complete disappearance of signal in 10 subjects. The presence of cancer-derived methylated DNA markers in plasma correlated with depth of tumor invasion and given the high rate of marker disappearance after cancer resection, the panel might also be useful to monitor tumor recurrence.

Graeme P. Young, MD, a professor of Gastroenterology and lead author of the study said, “A blood test is likely to overcome some of the barriers to screening with fecal tests. It might prove to be acceptable to those failing to participate in screening using established methods, which at the moment are primarily based around fecal tests.” The study was published on April 12, 2014, in the journal Gastrointestinal Endoscopy.

Related Links:

Flinders University 
Clinical Genomics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automated Clinical Chemistry Analyzer
Envoy 500+
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.